Phathom Pharmaceuticals presented 31 vonoprazan-related clinical abstracts at Digestive Disease Week 2026, including 28 independent studies and 3 Phathom-sponsored analyses. The research covered treatment of GERD, H. pylori eradication, long-term safety, and post-procedure care, reflecting growing scientific interest in vonoprazan and its class of acid blockers. A Phathom-sponsored Phase 3 trial analysis was recognized as a Poster of Distinction, underscoring vonoprazan's potential in gastrointestinal medicine. This expanding body of evidence may support broader clinical use and further development of vonoprazan-based therapies.
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Citigroup downgraded Apollo Global Management's stock from Buy to Reduce due to concerns over a potential economic slowdown and a sharp drop in U.S. private credit lending. Apollo's shares are trading well below their 52-week high, reflecting caution...
Conagra Brands reported its Q2 earnings with an EPS of $0.47, slightly beating estimates but down from last year. Revenue missed expectations at $2.88 billion, and the company announced a loss and a significant dividend cut as part of a new conservat...
